Terms ending in 2039
Every in-force patent on Chemocentryx, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,154,556 | Methods of Treating Solid Tumors with CCR2 Antagonists In force · High confidence | The Regents of the University of California | In force | High confidence | |
| US 11,207,294 | Methods of Treating Generalized Pustular Psoriasis with an Antagonist of CCR6 or CXCR2 In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,684,606 | Methods of Treating Generalized Pustular Psoriasis with an Antagonist of CCR6 or CXCR2 In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 12,758,558 | Methods of Treating Solid Tumors with CCR2 Antagonists In force · High confidence | The Regents of the University of California | In force | High confidence | |
| US 10,568,874 | Indane-Amines as PD-L1 Antagonists In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,135,210 | Indane-Amines as PD-L1 Antagonists In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,759,458 | Indane-Amines as PD-L1 Antagonists In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,478,460 | DIARYL SUBSTITUTED 6,5-Fused RING COMPOUNDS AS C5aR INHIBITORS In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 12,268,675 | DIARYL SUBSTITUTED 6,5-Fused RING COMPOUNDS AS C5aR INHIBITORS In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,485,737 | DIARYL SUBSTITUTED 5,5-Fused RING COMPOUNDS AS C5aR INHIBITORS In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| 8 more term ends in 2039 · Pro | |||||
10 of 18 patents shown. Soonest term end first, then patent number.
Pro members see all 18.
16 of these are in force and held by Chemocentryx, Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.